Cochlear Ltd.
Cochlear protests Medicare exclusion of Baha hearing implant
A proposed change to Medicare’s reimbursement of hearing aids could leave patients on their own when they need the a specific type of bone-anchored hearing aid implant, according to device maker Cochlear Ltd. (ASX:COH).
Cochlear lands breakthrough FDA win for Nucleus Hybrid L24 hearing aid
UPDATED March 21, 2013 with comments from Cochlear Americas president, principal investigator.
Jury slaps Cochlear Ltd. with $131M infringement verdict
Cochlear lands FDA clearance for Baha 4 bone conduction hearing
Cochlear Ltd. (ASX:COH) said landed 510(k) clearance from the FDA for its Baha 4 attract system, a bone conduction hearing system.
Cochlear Limited gets OK’d by FDA advisory panel
Cochlear Ltd. (ASX:COH) said an advisory committee to the FDA this week voted favorably on the Nucleus Hybrid L24 implant system, which combines acoustic amplification of low frequencies and electrical stimulation for high frequencies in a single device.
Cochlear’s hearing implant lands a date with the FDA
Cochlear Ltd. wins E.U. approval for tiny hearing device processor
Australian device company Cochlear Ltd. (ASX:COH) touted CE Mark approval in the European Union for the smallest behind-the-ear sound processor to hit European markets yet.
Sorin’s 2011 profits rise despite flat sales | Earnings Roundup
Sorin Group (BIT:SRN) managed to raise its bottom line despite flat sales for 2011 by raising its gross margin via restructuring, posting a profit increase of 48.3% for the year.
The Milanese cardiovascular device maker reported profits of $75.2 million (~€58.0 million) on sales of $963.4 million (~€743.4 million), compared with profits of $50.7 million (~€39.1 million) on sales of $966.5 million (~€745.8 million) during 2010.
Transvaginal mesh makers defend their devices, Riata leads poke holes during Irish study, Cochlear shares nosedive after recall | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Cochlear shares nosedive on hearing implant recall
Australian-based Cochlear Ltd. (ASX:COH), the world’s biggest maker of bionic ears, saw stocks drop by nearly 20 percent after a voluntary recall of its popular titanium hearing implants.
Cochlear recalled its Nucleus CI500 range of implants from shelves after an unexplained increase in failures in its CI512 implant model.